Overview Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus Status: Terminated Trial end date: 2004-12-01 Target enrollment: Participant gender: Summary The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus. Phase: Phase 3 Details Lead Sponsor: Takeda